ANALYSES OF HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

被引：0
|
作者：
DeRosa, M. [1 ]
Cocks, K. [2 ]
Taylor, F. [1 ]
Bobiak, S. [3 ]
Garcia, Juarez A. [3 ]
Shaw, J. W. [3 ]
机构：
[1] Adelphi Values, Boston, MA USA
[2] Adelphi Mill, Bollington, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN149
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [41] Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
    Ferris, Robert L.
    Blumenschein, George, Jr.
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa
    Harrington, Kevin J.
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis
    Saba, Nabil F.
    Iglesias Docampo, Lara Carmen
    Haddad, Robert
    Rordorf, Tamara
    Kiyota, Naomi
    Tahara, Makoto
    Lynch, Mark
    Jayaprakash, Vijayvel
    Li, Li
    Gillison, Maura L.
    ORAL ONCOLOGY, 2018, 81 : 45 - 51
  • [42] Cabazitaxel in patients with refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Results of phase II trial unicancer ORL03.
    Fayette, Jerome
    Guigay, Joel
    Le Toumeau, Christophe
    Degardin, Marian
    Peyrade, Frederic
    Orlandini, Florence
    Buffard, Karine
    Bellera, Carine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study
    Ueda, Yuri
    Okano, Susumu
    Enokida, Tomohiro
    Fujisawa, Takao
    Ito, Kazue
    Sato, Masanobu
    Tanaka, Hideki
    Wada, Akihisa
    Tahara, Makoto
    ORAL ONCOLOGY, 2022, 130
  • [44] A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
    Rischin, Danny
    Boyer, Michael J.
    Brzezniak, Christina E.
    Colevas, A. Dimitrios
    Doebele, Robert Charles
    Gilbert, Jill
    Gitlitz, Barbara
    Khan, Saad A.
    Mehra, Ranee
    Seiwert, Tanguy Y.
    Kroll, Stew
    Pearce, Tillman E.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
    Bossi, P.
    Merlano, M. C.
    Ghi, M. G.
    Rinaldi, G.
    Caponigro, F.
    Morelli, F.
    Airoldi, M.
    Farnesi, A.
    Cassano, A.
    Ferrari, D.
    Mirabile, A.
    Tosoni, A.
    Galizia, D.
    Moretti, G.
    Sponghini, A. P.
    Calareso, G.
    Vingiani, A.
    Perrone, F.
    Falletta, A.
    Licitra, L. F.
    ANNALS OF ONCOLOGY, 2019, 30 : 463 - 463
  • [46] Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and, neck (SCCHN) refractory to first-line platinum-based therapies.
    Vermorken, JB
    Bourhis, J
    Trigo, J
    Kies, M
    Leon, X
    Mueser, M
    Amellal, N
    Schueler, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 501S - 501S
  • [47] Cabazitaxel in patients with refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial UNICANCER ORL03
    Fayette, J.
    Guigay, J.
    Letourneau, C.
    Degardin, M.
    Peyrade, F.
    Orlandini, F.
    Buffard, K.
    Bellera, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S557 - S557
  • [48] Two-year follow-up of a randomized phaseIIIclinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate141)
    Yen, Chia-Jui
    Kiyota, Naomi
    Hanai, Nobuhiro
    Takahashi, Shunji
    Yokota, Tomoya
    Iwae, Shigemichi
    Shimizu, Yasushi
    Hong, Ruey-Long
    Goto, Masahiro
    Kang, Jin-Hyoung
    Li, Wing Sum Kenneth
    Ferris, Robert L.
    Gillison, Maura
    Endo, Toshimitsu
    Jayaprakash, Vijayvel
    Tahara, Makoto
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (10): : 2852 - 2862
  • [49] UPDATED RESULTS OF A RANDOMIZED, OPEN-PHASE II STUDY EXPLORING BIBW 2992 VERSUS CETUXIMAB IN PATIENTS WITH PLATINUM-REFRACTORY METASTATIC/RECURRENT HEAD AND NECK CANCER (SCCHN)
    Seiwert, T. Y.
    Fayette, J.
    Del Campo, J. M.
    Clement, P. M.
    Hitt, R.
    Cupissol, D.
    Degardin, M.
    Zhao, M.
    Thurm, H.
    Cohen, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 316 - 316
  • [50] Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience
    Bruixola, G.
    Caballero Daroqui, J.
    Cunquero Tomas, A. J.
    Sandiego, S.
    Garcia Sanchez, J.
    Blasco, S.
    Ochenduszko, S.
    Iranzo, A.
    Lavernia, J.
    Berrocal Jaime, A.
    Pastor Borgonon, M.
    ANNALS OF ONCOLOGY, 2018, 29
12345